CANTA Share Price | Cantargia AB Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Cantargia AB with Similar Stocks

Oncopeptides AB Xbrane Biopharma AB FluoGuide A/S

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Net Sales of INF%, the company declared Very Positive results in Dec 25

The company has declared positive results for the last 7 consecutive quarters
OPERATING CASH FLOW(Y) Highest at SEK 150.14 MM
NET PROFIT(HY) Higher at SEK 233.17 MM
ROCE(HY) Highest at 76.91%

With ROE of -537.32%, it has a does not qualify valuation with a 20.20 Price to Book Value

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 1,008 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.06

Return on Equity

55.28%

Price to Book

3.79

Revenue and Profits:

Net Sales:

8 Million

(Quarterly Results - Dec 2025)

Net Profit:

-32 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

150.91%

6 Months

129.76%

1 Year

-10.43%

2 Years

-7.19%

3 Years

-70.21%

4 Years

-81.75%

5 Years

-79.18%

Cantargia AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

216.52%

EBIT Growth (5y)

23.65%

EBIT to Interest (avg)

-258.06

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.49

Sales to Capital Employed (avg)

1.11

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

20.20

EV to EBIT

-3.40

EV to EBITDA

-3.47

EV to Capital Employed

-20.16

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-537.32%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 18.02% vs 44.74% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-30.70",
          "val2": "-39.70",
          "chgp": "22.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-32.30",
          "val2": "-39.40",
          "chgp": "18.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,921.10%",
          "val2": "0.00%",
          "chgp": "-392.11%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 190.91% vs 42.25% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "316.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "157.70",
          "val2": "-165.00",
          "chgp": "195.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "13.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "147.00",
          "val2": "-161.70",
          "chgp": "190.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "487.50%",
          "val2": "0.00%",
          "chgp": "48.75%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

8.00

0.00

Operating Profit (PBDIT) excl Other Income

-30.70

-39.70

22.67%

Interest

6.40

0.00

Exceptional Items

0.00

Consolidate Net Profit

-32.30

-39.40

18.02%

Operating Profit Margin (Excl OI)

-3,921.10%

0.00%

-392.11%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 18.02% vs 44.74% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

316.70

0.00

Operating Profit (PBDIT) excl Other Income

157.70

-165.00

195.58%

Interest

13.60

0.00

Exceptional Items

0.00

Consolidate Net Profit

147.00

-161.70

190.91%

Operating Profit Margin (Excl OI)

487.50%

0.00%

48.75%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 190.91% vs 42.25% in Dec 2024

All Annual Results

Company CV

About Cantargia AB

Cantargia AB

Pharmaceuticals & Biotechnology

Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

Company Coordinates

Company Details

Scheelevagen 27 , LUND None : 223 63

Tel: 46 46 275626046 46 2756260

http://www.cantargia.com

Registrar Details